[Mesenteric traction syndrome]

Ugeskr Laeger. 2014 Feb 17;176(8A):V09130546.
[Article in Danish]

Abstract

Mesenteric traction syndrome (MTS) manifests in 58-87% of patients undergoing upper abdominal surgery and is characterised by a triad of hypotension, tachycardia, and flushing. Prostacyclin is released from the gut mucosa following intestinal eventration and cyclooxygenase antagonists prevent the development of MTS. Also the use of remifentanil appears to increase the incidence of MTS and hypotension is aggravated by epidural analgesia. Yet, prostacyclin may be important for maintaining microcirculation within the splanchnic area and preserve its mucosal barrier.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Abdomen / surgery
  • Cyclooxygenase Inhibitors / therapeutic use
  • Epoprostenol / blood
  • Flushing / drug therapy
  • Flushing / physiopathology*
  • Humans
  • Hypotension / drug therapy
  • Hypotension / physiopathology*
  • Intraoperative Complications / physiopathology
  • Splanchnic Circulation / drug effects
  • Syndrome
  • Tachycardia / drug therapy
  • Tachycardia / physiopathology*

Substances

  • Cyclooxygenase Inhibitors
  • Epoprostenol